Results 1 to 10 of about 15,583 (116)

Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission

Redox Biology, 2018
Impaired cardiac microvascular function contributes to diabetic cardiovascular complications although effective therapy remains elusive. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor recently approved for treatment of type 2 diabetes,
Hao Zhou, Pingjun Zhu, Shunying Hu
exaly   +3 more sources

Empagliflozin Attenuates Global Cerebral Ischemic Injury After Cardiac Arrest Through Enhancing Ketone Body Oxidative Metabolism in Rats [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Cardiac arrest (CA) causes severe neurologic deficits and cognitive impairments. Empagliflozin is a newly developed antidiabetic drug and has been shown to reduce ischemia–reperfusion injury.
Peng Wang, Lian Liang, Yunke Tan, Qiulin Ge, Zitong Huang, Tao Yu   +5 more
doaj   +2 more sources

The Effect of Empagliflozin on Renal Outcomes in Patients With Established Cardiovascular Disease: Systematic Review and Meta‐Analysis of Randomised Placebo‐Controlled Trials [PDF]

Endocrinology, Diabetes & Metabolism
Background Empagliflozin, a sodium‐glucose cotransporter‐2 inhibitor (SGLT2i), may be associated with improved renal outcomes. However, the magnitude and potential heterogeneity of effect among patients with cardiovascular disease (CVD) remain unclear ...
Mansour Bahardoust, Fatemeh Naseri Rad, Sepideh Mousavi, Mohammadsadra Shamohammadi, Meisam Haghmoradi, Azin Ghaffari   +5 more
doaj   +2 more sources

Empagliflozin Inhibits Hepatic Gluconeogenesis and Increases Glycogen Synthesis by AMPK/CREB/GSK3β Signalling Pathway

Frontiers in Physiology, 2022
Increases in glucose production and decreases in hepatic glycogen storage induce glucose metabolic abnormalities in type 2 diabetes (T2DM). Empagliflozin, a sodium-dependent glucose transporter 2 (SGLT2) inhibitor, is an effective hypoglycemic drug ...
Xiaochen Yu, Ziyu Meng, Ting Fang, Xiaohuan Liu, Ying Cheng, Linxin Xu, Xiangyang Liu, Xiaoyu Li, Mei Xue, Ting Li, Bei Sun, Liming Chen   +11 more
doaj   +1 more source

Empagliflozin alleviates atherosclerotic calcification by inhibiting osteogenic differentiation of vascular smooth muscle cells

Frontiers in Pharmacology, 2023
SGLT-2 inhibitors, such as empagliflozin, have been shown to reduce the occurrence of cardiovascular events and delay the progression of atherosclerosis. However, its role in atherosclerotic calcification remains unclear.
Junping Li, Junping Li, Changping Li, Changping Li, Zhaoqi Huang, Zhaoqi Huang, Chunling Huang, Juanzhang Liu, Juanzhang Liu, Tao Wu, Tao Wu, Shuwan Xu, Peibiao Mai, Dengfeng Geng, Dengfeng Geng, Shuxian Zhou, Shuxian Zhou, Kun Zhang, Kun Zhang, Zhaoyu Liu   +19 more
doaj   +1 more source

Empagliflozin activates Wnt/β-catenin to stimulate FUNDC1-dependent mitochondrial quality surveillance against type-3 cardiorenal syndrome

Molecular Metabolism, 2022
Objectives: Cardiorenal syndrome type-3 (CRS-3) is an abrupt worsening of cardiac function secondary to acute kidney injury. Mitochondrial dysfunction is a key pathological mechanism of CRS-3, and empagliflozin can improve mitochondrial biology by ...
Chen Cai, Feng Wu, Bingjie Zhuang, Qing Ou, Xiaojie Peng, Nengxian Shi, Lan Peng, Ziying Li, Jin Wang, Shumin Cai, Ying Tan   +10 more
doaj   +1 more source

Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro

Frontiers in Pharmacology, 2021
Background: Metabolic associated fatty liver disease (MAFLD), characterized by hepatic lipid accumulation and fatty degeneration, is intertwined with obesity and type 2 diabetes mellitus (T2DM). Empagliflozin is a sodium-glucose cotransporter-2 inhibitor
Ting Li, Ting Fang, Linxin Xu, Xiangyang Liu, Xiaoyu Li, Mei Xue, Xiaochen Yu, Bei Sun, Liming Chen   +8 more
doaj   +1 more source

Sodium–Glucose Co-Transporter 2 Inhibition With Empagliflozin Improves Cardiac Function After Cardiac Arrest in Rats by Enhancing Mitochondrial Energy Metabolism

Frontiers in Pharmacology, 2021
Empagliflozin is a newly developed antidiabetic drug to reduce hyperglycaemia by highly selective inhibition of sodium–glucose co-transporter 2. Hyperglycaemia is commonly seen in patients after cardiac arrest (CA) and is associated with worse outcomes ...
Yunke Tan, Yunke Tan, Kai Yu, Kai Yu, Lian Liang, Lian Liang, Yuanshan Liu, Yuanshan Liu, Fengqing Song, Fengqing Song, Qiulin Ge, Qiulin Ge, Xiangshao Fang, Xiangshao Fang, Tao Yu, Tao Yu, Zitong Huang, Zitong Huang, Longyuan Jiang, Longyuan Jiang, Peng Wang, Peng Wang   +21 more
doaj   +1 more source

A randomized clinical trial evaluating the effect of empagliflozin on triglycerides in obese adults: Role of visceral fat

Metabolism Open, 2022
Background: Empagliflozin, a sodium glucose cotransporter 2 inhibitor, is a medication to treat type 2 diabetes. The effect of empagliflozin in persons without diabetes has received less attention.
Min Hee Lee, Ian J. Neeland, Natalia de Albuquerque Rocha, Connor Hughes, Craig R. Malloy, Eunsook S. Jin   +5 more
doaj   +1 more source

Empagliflozin: a potential anticancer drug

Discover Oncology, 2023
Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is a highly effective and well-tolerated antidiabetic drug. In addition to hypoglycemic effects, empagliflozin has many other effects, such as being hypotensive and cardioprotective.
Wenwen Wu, Yanyan Wang, Jun Xie, Shaohua Fan   +3 more
doaj   +1 more source